Zacks: Analysts Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Post -$0.19 EPS

Analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVSGet Rating) will post ($0.19) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings per share of ($0.28) during the same quarter last year, which indicates a positive year over year growth rate of 32.1%. The firm is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($0.89) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.81). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.58) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03).

CRVS has been the topic of a number of analyst reports. StockNews.com initiated coverage on Corvus Pharmaceuticals in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Corvus Pharmaceuticals in a research report on Friday, March 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.55.

NASDAQ CRVS opened at $1.07 on Tuesday. The business’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $2.21. Corvus Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $9.54.

In other news, CEO Richard A. Md Miller purchased 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The shares were acquired at an average cost of $1.47 per share, with a total value of $36,750.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Leiv Lea purchased 35,160 shares of the company’s stock in a transaction that occurred on Wednesday, March 16th. The shares were purchased at an average cost of $1.54 per share, for a total transaction of $54,146.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 80,160 shares of company stock worth $123,446. 45.12% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its holdings in Corvus Pharmaceuticals by 12.2% during the 1st quarter. State Street Corp now owns 112,603 shares of the company’s stock worth $185,000 after purchasing an additional 12,203 shares in the last quarter. Vanguard Group Inc. increased its holdings in Corvus Pharmaceuticals by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock worth $2,079,000 after purchasing an additional 36,002 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Corvus Pharmaceuticals by 72.6% during the 1st quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock worth $228,000 after purchasing an additional 58,952 shares in the last quarter. Jackson Square Capital LLC bought a new stake in Corvus Pharmaceuticals during the 1st quarter worth approximately $105,000. Finally, Hikari Power Ltd increased its holdings in Corvus Pharmaceuticals by 150.3% during the 1st quarter. Hikari Power Ltd now owns 49,959 shares of the company’s stock worth $82,000 after purchasing an additional 30,000 shares in the last quarter. 75.41% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile (Get Rating)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

Read More

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.